LEUCOVORIN CALCIUM (leucovorin calcium) by Viatris (2) is clinical pharmacology leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (thf). First approved in 1980.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
Leucovorin calcium is a reduced folate cofactor that counteracts the toxic effects of folic acid antagonists like methotrexate and enhances the therapeutic effects of fluoropyrimidines such as 5-fluorouracil in cancer therapy. It does not require enzymatic reduction and is rapidly metabolized to active metabolites that participate in one-carbon transfer reactions essential for DNA synthesis and repair. This oral tablet formulation is used as an adjunctive agent in cancer regimens to optimize efficacy and reduce toxicity.
As a mature generic with approaching loss of exclusivity, the brand team is likely focused on cost management and operational efficiency rather than growth initiatives.
CLINICAL PHARMACOLOGY Leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF). The biologically active compound of the mixture is the (-)- l -isomer, known as Citrovorum factor or (-)-folinic acid. Leucovorin does not require reduction by the enzyme…
Worked on LEUCOVORIN CALCIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis product offers minimal career growth opportunities given its mature, generic status and approaching loss of exclusivity. Positions are primarily operationally focused (manufacturing, supply chain, regulatory compliance) rather than commercially or scientifically innovative.